ライフサイエンスコーパス: brain tumor

1 ma multiforme (GBM) is the deadliest form of brain tumor.

2 nsiveness of this highly malignant pediatric brain tumor.

3 se and types of treatment in children with a brain tumor.

4 (MB) is the most common malignant pediatric brain tumor.

5 ty, visual field testing) in children with a brain tumor.

6 ch to the treatment of this uniformly lethal brain tumor.

7 c region of glioblastoma, the most malignant brain tumor.

8 in glioblastoma, a highly aggressive primary brain tumor.

9 onnectivity mapping over the life-cycle of a brain tumor.

10 gnant glioma (MG) is the most lethal primary brain tumor.

11 lastoma (GB) is the most devastating primary brain tumor.

12 lastoma, the most common malignant pediatric brain tumor.

13 rowth of glioblastoma (GBM), the most lethal brain tumor.

14 glioma (LGG), which is a slowly progressing brain tumor.

15 aging of T-cell trafficking in patients with brain tumor.

16 lastoma is the most common primary malignant brain tumor.

17 ng probe for this common malignant pediatric brain tumor.

18 , lung, ovary, pancreas, melanoma, bone, and brain tumors.

19 Ps have yet to be thoroughly investigated in brain tumors.

20 f constitutive PD-L1 and PD-L2 expression in brain tumors.

21 V glycoprotein (GP) might selectively target brain tumors.

22 tional MRI language mapping in patients with brain tumors.

23 promote the development of breast cancer and brain tumors.

24 ses and could potentially be tested in other brain tumors.

25 recurrent driver mutations in many pediatric brain tumors.

26 stoma and possibly other pediatric and adult brain tumors.

27 ematopoietic malignancies, solid tumors, and brain tumors.

28 new treatment paradigm for the treatment for brain tumors.

29 de gliomas are the most aggressive malignant brain tumors.

30 vel innate immune system-based therapies for brain tumors.

31 ion for improved delivery of chemotherapy to brain tumors.

32 ved from plasma specimens from patients with brain tumors.

33 o cervical, esophageal, pancreatic, lung and brain tumors.

34 mor, and the leading cause of death in adult brain tumors.

35 ionale for therapeutic inhibition of FGL2 in brain tumors.

36 lular matrix (ECM) are involved in malignant brain tumors.

37 ngiomas account for one-third of all primary brain tumors.

38 gene expression data derived from ependymoma brain tumors.

39 Glioblastomas are highly malignant brain tumors.

40 c declines in children treated for embryonal brain tumors.

41 val time of nude mice bearing orthotopic GBM brain tumors.

42 and dysregulated in neuropathologies such as brain tumors.

43 the routine clinical classification of adult brain tumors.

44 s well as in patients with untreated primary brain tumors.

45 iple BRAF inhibitor resistance mechanisms in brain tumors.

46 upts the BTB and enhances drug effusion into brain tumors.

47 clinical trials in patients with BRAF(V600E) brain tumors.

48 an reactivate an IDH1 mutant associated with brain tumors.

49 e survival of mice bearing established GL261 brain tumors.

50 developing PET imaging methods for pediatric brain tumors.

51 lassify the major histopathologic classes of brain tumors.

52 develop invasive or non-invasive neoplastic brain tumors.

53 mbosis in patients with benign and malignant brain tumors.

54 proved outcomes for children with aggressive brain tumors.

55 a key modality to evaluate disease status of brain tumors.

56 Gliomas are one of the most common types of brain tumors.

57 logical barriers to improve drug delivery to brain tumors.

58 ic therapies targeting neuroinflammation and brain tumors.

59 tional MRI language mapping in patients with brain tumors.

60 identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340

61 ared these workflows on a recently published brain tumor 450k DNA methylation cohort of 2,801 samples

62 ification networks to identify the pediatric brain tumor, adamantinomatous craniopharyngioma (ACP).

63 ly examined the immune profiles of pediatric brain tumors after immunotherapy.

64 oped iodine nanoparticles (INPs) that target brain tumors after intravenous (IV) injection.

65 antially better targeting and elimination of brain tumors after intravenous delivery and increased th

66 Glioma is the most common intrinsic brain tumor and also occurs in the spinal cord.

67 emains the most common and deadliest type of brain tumor and contains a population of self-renewing,

68 Glioblastoma (GBM) is the most aggressive brain tumor and resistant to current available therapeut

69 Meningiomas are the most common primary brain tumor and their incidence and prevalence is increa

70 (LGG) are the most common primary malignant brain tumors and are resistant to current therapies.

71 l to better understand the dynamic nature of brain tumors and glioma cells, including their invasion

72 me (GBM) is one of the most common malignant brain tumors and its average survival time is less than

73 ty of strokes occurs in patients treated for brain tumors and lymphomas; if >40, from cancers of the

74 lly represented in ATRTs compared with other brain tumors and non-neoplastic brain.

75 previously associated with moderate risk of brain tumors and other neoplasms.

76 ontrast scans to classify different types of brain tumors and predict tumor growth rate in a preclini

77 SAT1 expression is elevated in aggressive brain tumors and promotes resistance to radiotherapy.

78 delivery of therapeutic nucleic acids within brain tumors and provide a promising new delivery platfo

79 feasible in long-term survivors of pediatric brain tumors and that metformin is safe to use and toler

80 g medulloblastoma, the most common pediatric brain tumor, and basal cell carcinoma, the most common c

81 blastoma multiforme (GBM) is the most deadly brain tumor, and currently lacks effective treatment opt

82 er cells, including squamous cell carcinoma, brain tumor, and osteosarcoma, in addition to several no

83 cer, is the most lethal and common malignant brain tumor, and the leading cause of death in adult bra

84 ummarize recent progress in PARPi therapy in brain tumors, and discuss current opportunities for, and

85 g that is used to image Parkinson's disease, brain tumors, and focal hyperinsulinism of infancy.

86 y triple-negative breast cancer), leukemias, brain tumors, and many others.

87 setting of brain disease, including autism, brain tumors, and neurodegenerative disorders, microglia

88 oteins), there has been limited progress for brain tumor application partially because the low permea

89 ients aged 0-18 years with a newly diagnosed brain tumor are invited for inclusion in this study.

90 Pediatric brain tumors are the leading cause of childhood cancer-r

91 ecrease of regulatory T cells (Tregs) in the brain tumor area.

92 Medulloblastoma is a malignant childhood brain tumor arising from the developing cerebellum.

93 roven an effective tool for the treatment of brain tumors, arteriovenous malformation, and functional

94 upstream and a vein directly downstream of a brain tumor, as well as samples from dorsal pedal veins

95 s can enhance the permeability of the BTB in brain tumors, as well as disrupting the BBB in the surro

96 Glioblastoma is a hostile brain tumor associated with high infiltration leading to

97 were slight prevention effects on breast and brain tumor at the highest concentration.

98 he DVT patients with malignant versus benign brain tumors, atherosclerosis, hypertension, as well as

99 1028) provided as part of the Open Pediatric Brain Tumor Atlas (OpenPBTA) Project to determine recurr

100 d circulation, the blood-brain barrier/blood-brain tumor barrier (BBB/BBTB), and limited tumor uptake

101 d liposomes can effectively breach the blood-brain tumor barrier (BBTB) in vitro via GBM-induced angi

102 cell survival/proliferation, and survival in brain tumor-bearing mice treated with PT2385 alone and i

103 s and significantly prolongs the survival of brain tumor-bearing mice.

104 enous delivery and increased the survival of brain tumor-bearing mice.

105 a vital role for TNC in immunomodulation in brain tumor biology and demonstrate the prominence of th

106 boundaries to uncover foundational pediatric brain tumor biology and inform rational treatment select

107 loblastoma-the commonest malignant childhood brain tumor, but whether DDX3X functions as a medullobla

108 s the treatment of choice for most pediatric brain tumors, but early postoperative MRI for detection

109 is FDA-approved in the treatment of primary brain tumors, but its efficacy in patients with brain me

110 acy of dual-substrate drugs for treatment of brain tumors, but no marketed ABCB1/ABCG2 inhibitors are

111 roves preoperative planning in patients with brain tumors, but task-correlated signal intensity chang

112 adults increases the diagnostic accuracy for brain tumors, but the literature in pediatric neurooncol

113 hat can be used for efficient destruction of brain tumor by a combination of photodynamic and sonodyn

114 e propose parameter regimes that distinguish brain tumors by grade, thereby providing critical insigh

115 radiotherapy for the treatment of pediatric brain tumors by reducing the dose to normal tissue compa

116 our understanding of the genetics of primary brain tumors by uncovering several novel driver genetic

117 Since visual loss due to a brain tumor can be progressive and irreversible, we must

118 developmental disorders, trauma, stroke, and brain tumors can dramatically affect CNS functions resul

119 (MB), the most frequent malignant childhood brain tumor, can arise from cellular malfunctions during

120 We then employed a commonly used human brain tumor cell line to screen Food and Drug Administra

121 We found that a subset of brain tumor cell lines and BTICs expressed high constitu

122 as assessed by flow cytometry and qRT-PCR in brain tumor cell lines and patient tumor-derived brain t

123 y inhibiting glycolysis, ATP production, and brain tumor cell proliferation.

124 CK-NPs) can sequentially target BBB/BBTB and brain tumor cells with surface maltobionic acid (MA) and

125 lack of access, and the dispersed nature of brain tumor cells, we explore the possibility of electri

126 Glioblastoma is a primary malignant brain tumor characterized by highly infiltrative glioma

127 Glioblastoma (GBM) is the most malignant brain tumor characterized by intrinsic or acquired resis

128 Optic gliomas are brain tumors characterized by slow growth, progressive l

129 diology-Pathology (CPM-RadPath) Challenge on Brain Tumor Classification 2019 for tumor classification

130 se ratio and morphologic characterization of brain tumors compared with gadobenate, gadoterate, or ga

131 edulloblastoma (MB) is a pediatric malignant brain tumor composed of four different subgroups (WNT, S

132 Traditional therapies for malignant brain tumors consist of surgical resection and adjuvant

133 rs and children's hospitals in the Pediatric Brain Tumor Consortium (PBTC) scanned a phantom develope

134 The Pediatric Brain Tumor Consortium performed a multicentre, phase 2

135 raising the possibility that radiotherapy of brain tumors could promote tumor recurrence or trigger s

136 genetic factor contributing substantively to brain tumor development and to the success of therapy.

137 Medulloblastoma is a malignant brain tumor diagnosed in children.

138 ing for patient age, gender and histological brain tumor diagnosis (beta = -0.253, p < 0.001).

139 ined on over 2.5 million SRH images, predict brain tumor diagnosis in the operating room in under 150

140 , we identified Scm-like with four malignant brain tumor domains 1 (SFMBT1) as a candidate pVHL targe

141 Since 2010, 60 postmortem pediatric brain tumor donations from 26 institutions were coordina

142 .51 +/- 0.02 mum min(-1)) were comparable to brain tumor expansion rates measured in the clinic.

143 wards successful immunotherapy for pediatric brain tumors, focusing on pediatric high-grade glioma (H

144 edulloblastoma (MB) is a malignant pediatric brain tumor for which new therapies are urgently needed.

145 t of recurrent human Group 3 MB, a childhood brain tumor for which there is virtually no treatment op

146 ine gliomas (DIPGs) are aggressive pediatric brain tumors for which there is currently no effective t

147 n expression of a PGK1 Y324F mutant inhibits brain tumor formation.

148 ed cells and in in vivo LRP expressing mouse brain tumors ([Formula: see text], n = 10).

149 ncology Consortium Foundation, the Pediatric Brain Tumor Foundation, the Mithil Prasad Foundation, th

150 Brain tumors from control and irradiated mice were then

151 The aggressive primary brain tumor glioblastoma (GBM) is characterized by aberr

152 The aggressive brain tumor glioblastoma (GBM) is characterized by rapid

153 o investigate proteins altered in the deadly brain tumor glioblastoma.

154 Among high-grade brain tumors, glioblastoma is particularly difficult to

155 r, however, its efficacy in highly malignant brain-tumors, glioblastomas (GBM), is limited.

156 Brain tumors (gliomas) are heterogeneous cellular ecosys

157 lated with the DN:P ratio for the nontreated brain tumor group (P < .0001).

158 Brain tumor growth and tumor-induced edema result in inc

159 or cell apoptosis under hypoxia and inhibits brain tumor growth in mice.

160 -ALA can produce an inhibitory effect on rat brain tumor growth in the absence of thermal dose.

161 ated glycolytic pathways selectively impairs brain tumor growth while minimally impacting mammary tum

162 We found that 32% of brain tumors had at least one ctDNA alteration.

163 lioblastoma, the predominant adult malignant brain tumor, has been computationally classified into mo

164 Children with a brain tumor have a high risk of impaired vision.

165 Gliomas and other brain tumors have evaded durable therapies, ultimately c

166 Childhood brain tumors have suspected prenatal origins.

167 Children diagnosed with brain tumors have the lowest overall survival of all ped

168 oma (GBM), the most common primary malignant brain tumor, have been defined, the intricate signaling

169 and recurrently-fused genes within different brain tumor histologies.

170 (CED) provides direct access of infusates to brain tumors; however, clinical translation of this tech

171 ults from simulations, phantoms, healthy and brain tumor human subjects indicate improvements of glob

172 and device technologies for drug delivery to brain tumors, i.e., a flexible, sticky, and biodegradabl

173 c-based approaches with machine learning for brain tumor image analysis and prediction algorithm cons

174 ears; 76 men) included within the Multimodal Brain Tumor Image Segmentation (BraTS) dataset plus a cl

175 vation of both systemic and local privileged brain tumor immune response.

176 a (GBM) is the most common primary malignant brain tumor in adults and carries a dismal prognosis.

177 lastoma is the most common primary malignant brain tumor in adults and is associated with poor surviv

178 the most common and lethal primary malignant brain tumor in adults.

179 Glioblastoma is the most common primary brain tumor in adults.

180 a (GBM) is the most common malignant primary brain tumor in adults.

181 the most common and lethal primary malignant brain tumor in adults.

182 ltiforme (GBM) is the most common and deadly brain tumor in adults.

183 Medulloblastoma is the most common malignant brain tumor in children.

184 Glioblastoma (GBM), the most aggressive brain tumor in human patients, is decidedly heterogeneou

185 blastomas, the most malignant of all primary brain tumors in adults, is responsive to TOP2 poisons.

186 LO, a population-based case-control study of brain tumors in children and adolescents including saliv

187 One of the most common brain tumors in children and adults is glioma or astrocy

188 ulloblastoma (MB) is among the most frequent brain tumors in children less than 3 years of age.

189 s of visual impairment in different types of brain tumors in children.

190 oblastoma is among the most common malignant brain tumors in children.

191 ine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment.

192 how greater safety and efficacy in targeting brain tumors in immunodeficient mice when the MLD was ex

193 rticles (AuNPs) with RT could eradicate some brain tumors in mice and many other preclinical studies

194 ansgene expression throughout orthotopic rat brain tumors in vivo following administration by convect

195 a (MB) - the most common malignant pediatric brain tumor - includes prophylactic radiation administer

196 ignaling axis is efficacious against various brain tumors including GBM primarily by inducing tumor p

197 for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive

198 body can prospectively identify glioblastoma brain tumor initiating cells as well as human muscle ste

199 Oncogenic signaling by NOTCH is elevated in brain tumor-initiating cells (BTIC) in malignant glioma,

200 Brain tumor-initiating cells (BTICs) and orthotopic xeno

201 ently, both glioma stemlike cells (GSCs) and brain tumor-initiating cells (BTICs) have been implicate

202 n tumor cell lines and patient tumor-derived brain tumor-initiating cells (BTICs).

203 A brain tumor is an uncontrolled growth of cancerous cells

204 Metabolic reprogramming in brain tumors is also influenced by the tumor microenviro

205 rth pillar' of cancer treatment to pediatric brain tumors is an exciting but challenging prospect.

206 The efficacy of therapeutics for brain tumors is seriously hampered by multiple barriers

207 astrocytoma (PA), the most common childhood brain tumor, is a low-grade glioma with a single driver

208 Neutrophils isolated from mouse brain tumors kill cocultured tumor cells.

209 Glioblastomas are aggressive primary brain tumors known for their inter- and intratumor heter

210 Here, we identified Lethal(3)malignant brain tumor-like protein 1 (L3MBTL1) as a key regulator

211 glial progenitors and their contributions to brain tumor malignancy remain elusive.

212 ection margin, SM-OCT is able to resolve the brain tumor margin.

213 a xenograft model, SM-OCT readily identifies brain tumor margins with resolution of approximately 10

214 A solid brain tumor mass places compressive forces on adjacent n

215 NB development, but also strongly suppresses brain tumor mass, implicating a role for Para in cancer

216 assively recruited to reach up to 50% of the brain tumor mass.

217 cells-of-origin for the SHH-driven pediatric brain tumor medulloblastoma.

218 cluding ataxia and the most common pediatric brain tumor, medulloblastoma.

219 Our understanding of the brain tumor microenvironment (TME) remains limited, and

220 ibute to the immunosuppressive nature of the brain tumor microenvironment (TME).

221 potential impact of NAD(+) depletion on the brain tumor microenvironment has not been elaborated.

222 armustine (BCNU) was evaluated in an in vivo brain tumor model.

223 ry were used to monitor the therapy in a rat brain tumor model.

224 lting in regression of tumor in the in vitro brain tumor model.

225 his retrospective study, 700 two-dimensional brain tumor MRI scans from the Brain Tumor Segmentation

226 in a wide range of brain diseases including brain tumors, multiple sclerosis, Parkinson's disease, A

227 For patients with brain tumors, non-invasive diagnosis would represent a s

228 ows a new perspective on the role of AQP4 in brain tumors not necessarily associated with edema forma

229 Glioblastoma is an incurable brain tumor notorious for its heterogeneity.

230 most common and the most aggressive primary brain tumor of adults and children.

231 Conventional radiation therapy of brain tumors often produces cognitive deficits, particul

232 The DL network was able to locate brain tumors on the basis of training data that were lab

233 tion, and they further change with aging and brain tumor pathology.

234 forded discrimination of plasma derived from brain tumor patients relative to those derived from pati

235 Sixty-five percent (11/17) of brain tumor patients showed higher EV-GFAP than the maxi

236 signals.SIGNIFICANCE STATEMENT By comparing brain tumor patients to healthy children, we establish t

237 atives are feasible as PET imaging probes in brain tumor patients with activation of the kynurenine p

238 ved the way for new immune therapy trials in brain tumor patients.

239 glioma susceptibility loci on the pediatric brain tumor (PBT) risk and assessed the proportion of PB

240 Here, we describe a novel brain tumor predisposition syndrome that is caused by ge

241 ene expression in tumor cells in arbitrating brain tumor progression.

242 udies deciphering microenvironmental role in brain tumor progression.

243 ype A (PFA) ependymoma is a lethal pediatric brain tumor proposed to be driven solely by epigenetic d

244 an countries were retrieved from the Central Brain Tumor Registry of the United States (CBTRUS) and t

245 These include glial brain tumors, relapsed high-risk neuroblastoma, embryona

246 MB) is the most frequent malignant pediatric brain tumor, representing 20% of newly diagnosed childho

247 g to systematically evaluate patient-derived brain tumor responses.

248 p-21 and AAV-miR-7 in mice bearing malignant brain tumors resulted in significantly decreased tumor b

249 are explored in both mouse models and human brain tumors, revealing a novel opportunity for therapeu

250 lied annoFuse to fusion calls from pediatric brain tumor RNA-Seq samples (N = 1028) provided as part

251 The 2018 Multimodal Brain Tumor Segmentation Challenge (BraTS) dataset was u

252 apply the proposed methods to the Multimodal Brain Tumor Segmentation Challenge 2019 (BraTS 2019) dat

253 o-dimensional brain tumor MRI scans from the Brain Tumor Segmentation database were clinically interp

254 ork proposes context aware deep learning for brain tumor segmentation, subtype classification, and ov

255 ous fluidity for the invasive growth of soft brain tumors, showing that aggressive glioblastomas (GBM

256 entricle (LV) is a preferential location for brain tumor spread; however, the instructive cues respon

257 sm has on the survival of glioblastoma (GBM) brain tumor stem cells (BTSC) has not yet been elucidate

258 Glioblastoma brain tumor stem cells with low astrocytic glutamate tra

259 orty-nine PET/MRI brain scans were included: brain tumor studies using (18)F-fluoro-ethyl-tyrosine ((

260 ohort comparison design between 24 pediatric brain tumor survivors [11.81 +/- 3.27)] and 24 age match

261 Cognition is compromised in pediatric brain tumor survivors but the neurophysiological basis o

262 Compared to healthy children, pediatric brain tumor survivors show increased functional connecti

263 y band in the motor network within paedatric brain tumor survivors versus healthy children.

264 action time on behavioral tasks in pediatric brain tumor survivors.

265 lastoma (GBM) is the most commonly diagnosed brain tumor that exhibit high mortality rate and chemoth

266 Choroid plexus carcinoma (CPC) is a rare brain tumor that occurs most commonly in very young chil

267 Glioblastoma (GBM) is a brain tumor that remains largely incurable because of it

268 Glioblastomas are lethal brain tumors that are treated with conventional radiatio

269 Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and

270 for glioblastoma, one of the most aggressive brain tumors that remains incurable despite advancements

271 perative venous thrombosis, 78 patients with brain tumors that were operated on were studied, of whic

272 allow STICK-NPs to unleash the potential of brain tumor therapeutics to improve their treatment effi

273 es effective delivery of mAbs to the CNS for brain tumor therapy.

274 ance and ZIKV infection, providing potential brain tumor therapy.

275 glycol (PEG) coatings efficiently penetrate brain tumor tissue as well as healthy brain parenchyma.

276 in heathy rodent striatum and an aggressive brain tumor tissue established orthotopically in rats.

277 emic toxicity and inefficient penetration of brain tumor tissue even when it is placed directly in th

278 rate healthy brain parenchyma and orthotopic brain tumor tissues in rats.

279 iomic characterization methods for assessing brain tumors to improve noninvasive predictions of tumor

280 rgeting oncogenic pathways holds promise for brain tumor treatment, but inhibition of Sonic Hedgehog

281 rain barrier has been a promising method for brain tumor treatment.

282 dministration of GBCA occur in patients with brain tumors undergoing brain irradiation, as well as in

283 W/cm(2), the temperature within the targeted brain tumor was elevated from 32.3 +/- 0.5 degrees C and

284 The GRS for adult brain tumors was associated with an increased risk of PB

285 ne of the most prevalent childhood malignant brain tumors, were investigated to identify predisposing

286 egulation of cell proliferation in malignant brain tumors, which will have a broader impact on resear

287 ed and temporarily-extended drug delivery to brain tumors while minimizing unintended drug leakage to

288 .gov, NCT02040376) in survivors of pediatric brain tumors who had been treated with cranial radiation

289 handed, left-language-dominant patients with brain tumors who successfully performed verb generation,

290 Glioblastoma multiforme (GBM) is a malignant brain tumor with a poor prognosis resulting from tumor r

291 erior fossa A ependymoma, a lethal pediatric brain tumor with a silent genome, is dependent upon meta

292 forme (GBM) is a highly aggressive malignant brain tumor with fatal outcome.

293 blastoma is a highly heterogeneous pediatric brain tumor with five molecular subtypes, Sonic Hedgehog

294 Glioblastoma (GBM) is an astrocytic brain tumor with median survival times of <15 months, pr

295 trinsic pontine gliomas (DIPG) are incurable brain tumors with an aggressive onset.

296 -PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies.

297 ent SCID mice, we focused on targeting human brain tumors with these VSV-EBOVs.

298 tine glioma (DIPG) is an incurable pediatric brain tumor, with approximately 25% of DIPGs harboring a

299 tomas (GBMs) are the most aggressive primary brain tumors, with an average survival of less than 15 m

300 or (AT/RT) is an aggressive, early-childhood brain tumor without standard effective treatment.